Tolerance is the holy grail in calming autoimmune disease, a truce in the immune system’s faulty battle against the body’s own fabric. In type 1 diabetes, immune fighters attack beta cells in the pancreas that produce insulin, the hormone that controls glucose levels in the blood.
Scientists have tried to enlist defenders in the form of regulatory T-cells, or Tregs, extra white blood cells whose job is to tamp down the misguided immune response. A paper published Wednesday in Science Translational Medicine describes a Phase 2 clinical trial that infused an expanded version of patients’ own Tregs into 110 children and adolescents newly diagnosed with type 1 diabetes. It was intended to preserve their remaining insulin-making cells.
Click this link for the original source of this article.
Author: Elizabeth Cooney
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.